Unravelling the general properties of siRNAs: Strength in numbers and lessons from the past

Nature Reviews Genetics

Volumn 5, Issue 7, 2004, Pages 552-557

  Hall, Jonathan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; SMALL INTERFERING RNA; MICRORNA; OLIGONUCLEOTIDE;

BIOINFORMATICS; CAENORHABDITIS ELEGANS; DNA MICROARRAY; GENE SILENCING; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSFECTION; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; RNA INTERFERENCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DROSOPHILA MELANOGASTER; METABOLISM;

CAENORHABDITIS; CAENORHABDITIS ELEGANS;

ANIMALS; CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER; GENOME; HUMANS; MICRORNAS; MODELS, GENETIC; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING;

EID: 3042762351     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1382     Document Type: Review

References (59)

1. Ashrafi, K. et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421, 268-272 (2003).
2. Boutros, M. et al. Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303, 832-836 (2004).
3. Caplen N. J., Parrish S., Imani F., Fire A. & Morgan R. A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl Acad. Sci. USA 98, 9742-9747 (2001).
4. Bass, B. L. RNA interference: the short answer. Nature 411, 428-429 (2001).
5. Howard, K. Unlocking the money-making potential of RNAi. Nature Biotechnol., 21, 1441-1446 (2003).
6. Frankish, H. Consortium uses RNAi to uncover genes' function. Lancet 361, 584 (2003).
7. Paddison, P. et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 426, 427-431 (2004).
8. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
9. Mittal, V. Improving the efficiency of RNA interference in mammals. Nature Rev. Genet. 5, 355-365 (2004).
10. Freier, S. M. et al. in Gene Regulation by Antisense Nucleic Acids (Raven Press Series on Molecular and Cellular Biology, Vol. 1) (eds Ivant, J. & Erickson, R.) 95-107 (Raven, New York, 1992).
11. Tidd, D. M. & Giles, R. V. In Pharmaceutical Aspects of Oligonucleotides (eds Couvreur, P. & Malvy, C.) Part I, 3-31 (Taylor and Francis, London, 2000).
12. Stein, C. A. Is irrelevant cleavage the price of antisense efficacy? Pharmacol. Ther. 85, 231-236 (2000).
13. Giles, R. V., Ruddell, C. J., Spiller, D. G., Green, J. A. & Tidd. D. M. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukemia cells. Nucleic Acids Res. 23, 954-961 (1995).
14. Harborth, J., Elbashir, S. M., Bechert, K., Tuschl, T. & Weber, K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell Sci. 114, 4557-4565 (2001).
15. Elbashir, S. M., Harborth, J., Weber, K. & Tuschl, T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26, 199-213 (2002).
16. Miller, V. et al. Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA 100, 7195-7200 (2003).
17. Abdelgany, A., Wood, M. & Beeson, D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum. Mol. Genet. 12, 2637-2644 (2003).
18. Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589-595 (2003).
19. Chiu, Y.-L. & Rana, T. M. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-1048 (2003).
20. Pusch, O. et al. Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. Nucleic Acids Res. 31, 6444-6449 (2003).
21. Lewis, B. P., Shih, I.-h., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. Cell 115, 787-798 (2003).
22. Doench, J. G. & Sharp, P. A. Specificity of microRNA target selection in translational repression. Genes Dev. 18, 504-511 (2004).
23. Scacheri, P. C. et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl Acad. Sci. USA 101, 1892-1897 (2004).
24. Zeng, Y., Wagner, E. J. & Cullen, B. R. Both natural and designed microRNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9, 1327-1331 (2002).
25. Zeng, Y., Yi, R. & Cullen, B. R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl Acad. Sci. USA 100, 9779-9784 (2003).
26. Doench, J. G., Petersen, C. P. & Sharp, P. A. siRNAs can function as miRNAs. Genes Dev. 17, 438-442 (2003).
27. Saxena, S., Jonsson, Z. O. & Dutta, A. Small RNAs with imperfect match to endogenous mRNA repress translation: implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 278, 44312-44319 (2003).
28. Chi, J.-T. et al. Genome-wide view of gene silencing by small interfering RNAs. Proc. Natl Acad. Sci. USA 100, 6343-6346 (2003).
29. Jackson, A. L., et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635-637 (2003).
30. Semizarov, D. et al. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl Acad. Sci. USA 100, 6347-6352 (2003).
31. Persengiev, S. P., Zhu, X. & Green, M. R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12-18 (2004).
32. Kim, D.-H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nature Biotechnol. 22, 321-325 (2004).
33. Ganju, P. & Hall, J. Potential applications of siRNA for pain therapy. Expert Opin. Biol. Ther. 4, 531-542 (2004).
34. Harborth, J. et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13, 83-105 (2003).
35. Kumar, R., Conklin, D. S. & Mittal, V. High-throughput selection of effective RNAi probes for gene silencing. Genome Res. 13, 2333-2340 (2003).
36. Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E. & Prydz, H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 30, 1757-1766 (2002).
37. Vickers, T. A. et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108-7118 (2003).
38. Khvorova, A., Reynolds, A. & Jayasena, S. D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209-216 (2003).
39. Schwarz, D. S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208 (2003).
40. Reynolds, A. et al. Rational siRNA design for RNA interference. Nature Biotechnol. 22, 326-330 (2004).
41. Ui-Tei, K. et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference Nucleic Acids Res. 32, 936-948 (2004).
42. Hsieh, A. C. et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res. 32, 893-901 (2004).
43. Amarzguioui, M. & Prydz, H. An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 316, 1050-1058 (2004).
44. Giddings, M. C. et al. Artificial neural network prediction of antisense oligodeoxynucleotide activity. Nucleic Acids Res. 30, 4295-4304 (2002).
45. Kretschmer-Kazemi, F. R. & Sczakiel, G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 31, 4417-4424 (2003).
46. Lima, W. F., Monia, B. P., Ecker, D. J. & Freier S. M. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31, 12055-12061 (1992).
47. Yoshinari, K., Miyagishi, M. & Taira, K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 32, 691-699 (2004).
48. Frantz, S. Studies reveal potential pitfalls of RNAi. Nature Rev. Drug Discov. 2, 763-764 (2003).
49. Monia, B. P. et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267, 19954-19962 (1992).
50. Wahlestedt, C. et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA 97, 5633-5638 (2000).
51. McCaffrey, A. P., Meuse, L., Karimi, M., Contag, C. H. & Kay, M. A. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38, 503-508 (2003).
52. Pancoska, P., Moravek, Z. & Moll, U. M. Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA. Nucleic Acids Res. 32, 1469-1479 (2004).
53. Freier, S.M. in Antisense Research and Applications (Eds Crooke, S. T. & Lebleu, B.) Ch. 5 (CRC Press, Boca Raton, Florida, 1993).
54. Donze, O. & Picard, D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res. 30, e46 (2002).
55. Miyagishi, M. & Taira, K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nature Biotechnol. 20, 497-500 (2002).
56. Lee, N. S., et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnol. 20, 500-505 (2002).
57. Nykanen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309-321 (2001).
58. Djikeng, A., Shi, H., Tschudi, C., Shen, S. & Ullu, E. An siRNA ribonucleoprotein is found associated with polyribosomes in Trypanosoma brucei. RNA 9, 802-808 (2003).
59. Ishizuka, A., Siomi, M. C. & Siomi, H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev. 16, 2497-2508 (2002).